W

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

Business Management
Share
Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

Source：MarketWatch

Disclaimer：Please read market information rationally and stay aware of investment risks. All content on this site is for informational purposes only and does not constitute investment advice.

Related Reading

Hardware wallet sales in Russia more than double as new crypto rules near

Wildberries’ average price for hardware wallets fell 13% to 7,900 rubles, and M.Video broadened its range of products, though neither retailer identified the…

US spot Bitcoin ETFs post best week since April with $1B inflows

The spot Bitcoin exchangetraded funds registered their thirdstrongest showing since October as institutional demand showed signs of renewed momentum.…

Brazil's central bank orders exchanges to delay large crypto transfers abroad

The rule applies to transfers above $10,000 and smaller transactions flagged as risky by exchanges. Source：CoinDesk

US Senate to vote on advancing CLARITY Act in September after Thune files cloture

The procedural move puts crypto market structure legislation back on track as lawmakers continue negotiations over ethics and stablecoin provisions.…

Source：https://www.marketwatch.com/story/novo-nordisks-stock-slumps-after-failed-trial-adding-to-the-companys-woes-202419cd